Results 111 to 120 of about 35,436 (198)

Exosome‐Mediated Delivery of PROTACs for Targeted Protein Degradation in Cancer, Neurodegenerative, Infectious, and Inflammatory Diseases

Journal of Cellular and Molecular Medicine, Volume 30, Issue 15, August 2026.
ABSTRACT Proteolysis‐targeting chimeras (PROTACs) are heterobifunctional molecules that hijack the ubiquitin‐proteasome system to drive catalytic, sub‐stoichiometric degradation of disease‐associated proteins, offering a mechanistic advantage over occupancy‐driven inhibitors and access to ‘undruggable’ targets.
Sruti Bagchi Ghosh, Rumpa Banerjee, Hailah M. Almohaimeed, Amany I. Almars, Tahani Ahmad ALMatrafi, Fayez M. Saleh, Zuhair M. Mohammedsaleh, Kranti Kiran Reddy Ealla, Ajoy Kumer, Bikram Dhara   +9 more
wiley   +1 more source

Intact proviruses are enriched in the colon and associated with PD-1+TIGIT− mucosal CD4+ T cells of people with HIV-1 on antiretroviral therapyResearch in context

EBioMedicine
Summary: Background: The persistence of intact replication-competent HIV-1 proviruses is responsible for the virological rebound off treatment. The gut could be a major reservoir of HIV-1 due to the high number of infected target cells.
Camille Vellas, Manon Nayrac, Nived Collercandy, Mary Requena, Nicolas Jeanne, Justine Latour, Chloé Dimeglio, Michelle Cazabat, Karl Barange, Laurent Alric, Nicolas Carrere, Guillaume Martin-Blondel, Jacques Izopet, Pierre Delobel   +13 more
doaj   +1 more source

Latency Reversing Agents and the Road to an HIV Cure

Pathogens
HIV-1 infection cannot be cured due to the presence of HIV-1 latently infected cells. These cells do not produce the virus, but they can resume virus production at any time in the absence of antiretroviral therapy. Therefore, people living with HIV (PLWH)
Louis Tioka, Rafael Ceña Diez, Anders Sönnerborg, Maarten A. A. van de Klundert   +3 more
doaj   +1 more source

Positioning HIV SMRTcap within the HIV reservoir toolbox. [PDF]

PLoS Pathog
Loddo A, Delobel P, Vellas C.
europepmc   +1 more source

Is the molecular microenvironment of the latent HIV reservoir predictable using deep learning approaches? [PDF]

J Virol
Chen H-C.
europepmc   +1 more source

Allograft Rejection and the Latent HIV Reservoir in Kidney Transplant Recipients with HIV. [PDF]

J Infect Dis
Sulaiman A, Tamil Selvan M, Yang P, Zhu X, Eby Y, Benner SE, Fernandez RE, Hussain S, Brown D, Desai N, Florman S, Rana MM, Friedman-Moraco R, Pereira MR, Mehta S, Stock P, Gilbert A, Morris MI, Stosor V, Mehta SA, Small CB, Ranganna K, Santos CAQ, Aslam S, Malinis M, Elias N, Blumberg EA, Massie A, Smith ML, Morsheimer M, Laird GM, Siliciano R, Segev DL, Durand CM, Redd AD, Tobian AA.   +35 more
europepmc   +1 more source

The latent HIV reservoir: current advances in genetic sequencing approaches. [PDF]

mBio, 2023
Moar P, Premeaux TA, Atkins A, Ndhlovu LC.   +3 more
europepmc   +1 more source

Q4ddPCR: a flexible, 4-target assay for high-resolution HIV reservoir profiling. [PDF]

Nat Commun
Scheck R, Melzer M, Gladkov G, Leyre L, Ward AR, Reeves DB, Perkins N, Huynh TT, McMahon DK, Bosch RJ, Macatangay BJ, Cyktor JC, Eron JJ, Mellors JW, Gandhi RT, Buchauer L, Jones RB, Gaebler C.   +17 more
europepmc   +1 more source

Targeting the HIV reservoir: chimeric antigen receptor therapy for HIV cure. [PDF]

Chin Med J (Engl), 2023
Li S, Wang H, Guo N, Su B, Lambotte O, Zhang T.   +5 more
europepmc   +1 more source

Targeting PD-1⁺ T cells with chimeric antigen receptors to reduce the HIV reservoir. [PDF]

Sci Adv
Ermellino L, Banga R, Georgakis S, Kadzioch NP, Procopio F, Alcaraz-Serna A, Alfageme-Abello O, Porret R, Cecchin R, Orfanakis M, Schelling R, Brenna C, Can DC, Foglierini M, Chén OY, Perez L, Fenwick C, Perreau M, Petrovas C, Speck RF, Pantaleo G, Muller YD.   +21 more
europepmc   +1 more source